HROW Rasio cepet Harrow, Inc.

Harrow, Inc. (HROW) holds a leading position in the US prescription eye drop segment, leveraging a broad portfolio of brands to hedge against regulatory threats. The business relies on the consolidation of the ophthalmology market, providing physicians with comprehensive therapeutic solutions. Stability of production is guaranteed by a network of proven contract manufacturing plants, and the current figure is 2.14. The company's share price history is presented below.

This indicator measures the ability of Harrow, Inc. (HROW) to instantaneously settle short-term liabilities using exclusively cash and accounts receivable, excluding inventory. Regular monitoring of the quick ratio confirms the financial stability of Harrow, Inc., as steady demand for ophthalmology drugs ensures a predictable cash inflow, minimizing the risks associated with reliance on inventory liquidation.